1. Home
  2. ULY vs LYRA Comparison

ULY vs LYRA Comparison

Compare ULY & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Urgent.ly Inc.

ULY

Urgent.ly Inc.

HOLD

Current Price

$2.15

Market Cap

4.8M

Sector

N/A

ML Signal

HOLD

Logo Lyra Therapeutics Inc.

LYRA

Lyra Therapeutics Inc.

HOLD

Current Price

$1.31

Market Cap

5.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ULY
LYRA
Founded
2013
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.8M
5.6M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
ULY
LYRA
Price
$2.15
$1.31
Analyst Decision
Strong Buy
Hold
Analyst Count
2
1
Target Price
$11.50
$16.00
AVG Volume (30 Days)
400.4K
71.6K
Earning Date
03-11-2026
03-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$127,932,000.00
$600,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$18.95
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.74
$1.21
52 Week High
$17.99
$37.50

Technical Indicators

Market Signals
Indicator
ULY
LYRA
Relative Strength Index (RSI) 46.49 29.93
Support Level $2.01 $1.21
Resistance Level $2.23 $2.05
Average True Range (ATR) 0.37 0.22
MACD -0.01 0.00
Stochastic Oscillator 19.64 10.33

Price Performance

Historical Comparison
ULY
LYRA

About ULY Urgent.ly Inc.

Urgently Inc is a connected mobility assistance software platform, matching vehicle owners and operators with service professionals who deliver traditional roadside assistance, proactive maintenance and repair services. The traditional experience of a vehicle breakdown is often stressful and inconvenient, compounded by processes that lack transparency and to long wait times. Urgently offers an alternative to this traditional experience, leveraging its digitally native software platform to match supply and demand in its network and deliver exceptional mobility assistance experiences at scale.

About LYRA Lyra Therapeutics Inc.

Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.

Share on Social Networks: